Mac, who suffered from sarcoidosis, battled this inflammatory disease for years, which severely affected his lungs and immune ...
notes that, The journey to combat MAC lung disease starts with an oral antibiotic regimen according to clinical studies, for ...
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and ...
American Lung Association: “Learn about NTM Lung Disease.” Tuberculosis & Respiratory Diseases: “Treatment of Mycobacterium avium Complex Pulmonary Disease.” Indian Journal of Medical ...
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.